Aligos Therapeutics vs Molecular Partners
ALGS and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALGS and MOLN compare
Aligos Therapeutics grew revenue faster over the last twelve months (122% versus −100% for Molecular Partners).
Aligos Therapeutics scores higher on the StockData Score (7 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALGS | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $27.0M | – |
| Share price | $2.16 | $3.09 |
| Change, 1 year | −68.6% | −27.3% |
| Change, 5 years | −99.5% | −70.4% |
| Beta (5Y) | 1.51 | 0.90 |
| Employees | 82 | 34 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.6× | – |
| P/B | 2.4× | – |
| Fair value | $2.40 | – |
| Margin of safety | 9.9% | – |
| Growth | ||
| Revenue growth (TTM) | 122% (better) | −100% |
| Profitability | ||
| Operating margin | −1244% | – |
| Net margin | −1137% | – |
| Return on equity | −159% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −11.5× |
| Current ratio | 1.77 | 7.27 (better) |
| Altman Z-score | −24.54 | – |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 18.4% | 8.9% |
| Held by insiders | – | 0.00% |
| Superinvestors holding | 1 | – |
Go deeper
- ALGS stock overview
- ALGS income statement
- ALGS valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.